Funding Support and Author Disclosures Dr Oren has received funding from the National Institutes of Health (grant T32HL007208, Integrated, Multidisciplinary Training in Cardiovascular Research, Clonal Hematopoiesis and Venous Thromboembolism). Dr Small has received funding from the Doris Duke Clinical Foundation Physician Scientist Fellowship. Dr Lin has received funding from the University of California-San Francisco, Cardiology Scholars and Innovations Award. Dr Libby has received funding support from the National Heart, Lung, and Blood Institute (grants R01HL170000, 1R01HL163099-01, R01AG063839, R01HL151627, R01HL157073, and R01HL166538), and the RRM Charitable Fund. Dr Libby is an unpaid consultant to or is involved in clinical trials for Amgen, the Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Novo Nordisk, Novartis, and Sanofi-Regeneron; is a member of the scientific advisory boards of Amgen, Caristo Diagnostics, CSL Behring, Elucid Bioimaging, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, Novartis, PlaqueTec, Polygon Therapeutics, TenSixteen Bio, Soley Therapeutics, and XBiotech; has received research funding to his laboratory in the past 2 years from Novartis, Novo Nordisk, and Genentech; is on the board of directors of XBiotech; and has a financial interest in Xbiotech (a company developing therapeutic human antibodies), TenSixteen Bio (a company targeting somatic mosaicism and CHIP to discover and develop novel therapeutics to treat age-related diseases), and Soley Therapeutics (a biotechnology company that is combining artificial intelligence with molecular and cellular response detection for discovering and developing new drugs, currently focusing on cancer therapeutics). Dr Libby’s interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.